KATELYN BUYARSKI: Open Payments
NPI 1033750245 · BLOOMSBURG, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,152 in 57 payments from 16 companies in 2025. Trend: 2023 $43 · 2024 $216 · 2025 $1,152
Food & beverage: $1,152
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $258 |
| Novo Nordisk Inc | 9 | $198 |
| AstraZeneca Pharmaceuticals LP | 7 | $158 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $84 |
| Exact Sciences Corporation | 3 | $73 |
| Esperion Therapeutics, Inc. | 3 | $60 |
| Lilly USA, LLC | 3 | $59 |
| Merck Sharp & Dohme LLC | 3 | $56 |
| Indivior Inc. | 2 | $35 |
| Amgen Inc. | 2 | $33 |
Products named: VRAYLAR, Kerendia, Wegovy, QULIPTA, AIRSUPRA, FARXIGA, NEXLETOL, MOUNJARO.
Industry payments across PA — which companies pay providers there.
